No Data
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (Vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals to Host Webcast to Review Interim Data From Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
Express News | Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est
Ginvest : Thank you for the timely info
Srav Reddy : $X4 Pharmaceuticals (XFOR.US)$ announcement was early on 29/4. But price receded. This is surprising to me.